Dr. Miguel Valderrábano and his team aim to evaluate the long-term efficacy and outcomes of retrograde venous ethanol ablation in treating ventricular arrhythmias through the VENUS trial published in JAMA. The team found that retrograde coronary venous ethanol ablation (RCVEA) can be effective for radiofrequency ablation (RFA)- refractory VAs, particularly those arising in the LV summit (LVS).